A study highlights insufficient standardized safety and efficacy assessments for FDA-cleared AI/ML medical devices.
Key Details
- 1Cross-sectional analysis of FDA-cleared AI/ML-enabled devices was conducted.
- 2The study found lack of standardized efficacy and safety reporting in device clearance.
- 3Suggested need for dedicated regulatory pathways and post-market AI/ML safety surveillance.
- 4Study was published in JAMA Health Forum and led by Dr. Ravi B. Parikh.
Why It Matters
As imaging AI tools increasingly enter clinical use, robust regulatory oversight is critical for patient safety and clinician trust. Gaps in FDA reporting and surveillance could impact the safe integration of AI in radiology practice.
Source
EurekAlert
Related News
•EurekAlert
AI Tool Predicts Financial Toxicity Risk in Cancer Patients
Researchers developed a machine learning model to proactively identify cancer patients at high risk of financial stress from treatment.
•EurekAlert
Researchers Develop All-Optical Synapse for Neuromorphic Imaging Systems
A new artificial synapse, controlled entirely by light, enables in-sensor neuromorphic processing for more efficient and noise-resistant imaging systems.
•EurekAlert
AI-Simulation Approach Achieves 90% Faster Brain MRI with Minimal Data
A simulation-based AI method can reconstruct brain MRI scans with only 10% of the usual data, greatly reducing scan times.